Wong J, Chan KY, Lo K, et al. - According to this systematic review and meta-analysis, sodium-glucose cotransporter 2 (SGLT-2) inhibitor monotherapy for at least 12 weeks can result in modest weight loss in patients who are overweight or obese but do not have diabetes. SGLT-2 inhibitors can be used as adjuncts in the treatment of obesity, depending on pre-existing comorbidities or risk factors.

• In total, eight randomized controlled trials with 750 individuals have been identified.

• SGLT-2 monotherapy was linked to a significant decline in body weight of −2.32 kg, compared with −1.01 kg for placebo, with a mean difference of −1.31 kg.

• Significant reductions in BMI and fasting blood glucose were seen, but not in waist circumference, fat mass, blood pressure, or lipid profile when compared with placebo.